Cathay Biotech Inc (688065) - Net Assets

Latest as of September 2025: CN¥21.22 Billion CNY ≈ $3.10 Billion USD

Based on the latest financial reports, Cathay Biotech Inc (688065) has net assets worth CN¥21.22 Billion CNY (≈ $3.10 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥23.45 Billion ≈ $3.43 Billion USD) and total liabilities (CN¥2.23 Billion ≈ $326.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Cathay Biotech Inc to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥21.22 Billion
% of Total Assets	90.5%
Annual Growth Rate	36.97%
5-Year Change	31.49%
10-Year Change	N/A
Growth Volatility	47.23

Cathay Biotech Inc - Net Assets Trend (2016–2024)

This chart illustrates how Cathay Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore 688065 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Cathay Biotech Inc (2016–2024)

The table below shows the annual net assets of Cathay Biotech Inc from 2016 to 2024. For live valuation and market cap data, see market cap of Cathay Biotech Inc.

Year	Net Assets	Change
2024-12-31	CN¥15.10 Billion ≈ $2.21 Billion	+2.22%
2023-12-31	CN¥14.77 Billion ≈ $2.16 Billion	-1.76%
2022-12-31	CN¥15.04 Billion ≈ $2.20 Billion	+2.39%
2021-12-31	CN¥14.69 Billion ≈ $2.15 Billion	+27.89%
2020-12-31	CN¥11.48 Billion ≈ $1.68 Billion	+147.41%
2019-12-31	CN¥4.64 Billion ≈ $679.25 Million	+47.05%
2018-12-31	CN¥3.16 Billion ≈ $461.93 Million	+43.70%
2017-12-31	CN¥2.20 Billion ≈ $321.46 Million	+80.24%
2016-12-31	CN¥1.22 Billion ≈ $178.35 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Cathay Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 240549132600.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥2.31 Billion	20.04%
Common Stock	CN¥583.38 Million	5.07%
Other Comprehensive Income	CN¥359.64 Million	3.13%
Other Components	CN¥8.26 Billion	71.76%
Total Equity	CN¥11.51 Billion	100.00%

Cathay Biotech Inc Competitors by Market Cap

The table below lists competitors of Cathay Biotech Inc ranked by their market capitalization.

Company	Market Cap
Sectra AB (publ) ST:SECT-B	$5.02 Billion
Glarun Technology Co Ltd SHG:600562	$5.02 Billion
Beijing Jingneng Power Co Ltd SHG:600578	$5.03 Billion
Genesis Minerals Ltd AU:GMD	$5.03 Billion
CHINA TOWER UNSP.ADR/100 F:2Y10	$5.02 Billion
Housing & Urban Development Corporation Limited NSE:HUDCO	$5.02 Billion
Corporacion Financiera Alba SA MC:ALB	$5.02 Billion
Red Avenue New Materials Group Co Ltd SHG:603650	$5.01 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cathay Biotech Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 11,164,180,631 to 11,507,005,495, a change of 342,824,864 (3.1%).
Net income of 488,961,919 contributed positively to equity growth.
Dividend payments of 140,834,553 reduced retained earnings.
Share repurchases of 28,933,667 reduced equity.
Other comprehensive income increased equity by 133,801,204.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥488.96 Million	+4.25%
Dividends Paid	CN¥140.83 Million	-1.22%
Share Repurchases	CN¥28.93 Million	-0.25%
Other Comprehensive Income	CN¥133.80 Million	+1.16%
Other Changes	CN¥-110.17 Million	-0.96%
Total Change	CN¥-	3.07%

Book Value vs Market Value Analysis

This analysis compares Cathay Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.41x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 14.17x to 2.41x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	CN¥3.36	CN¥47.60	x
2017-12-31	CN¥6.06	CN¥47.60	x
2018-12-31	CN¥8.70	CN¥47.60	x
2019-12-31	CN¥12.83	CN¥47.60	x
2020-12-31	CN¥27.12	CN¥47.60	x
2021-12-31	CN¥25.66	CN¥47.60	x
2022-12-31	CN¥18.80	CN¥47.60	x
2023-12-31	CN¥19.19	CN¥47.60	x
2024-12-31	CN¥19.77	CN¥47.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cathay Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.25%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 16.53%
• Asset Turnover: 0.16x
• Equity Multiplier: 1.65x
Recent ROE (4.25%) is below the historical average (8.30%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	11.94%	15.66%	0.56x	1.36x	CN¥23.59 Million
2017	15.15%	24.42%	0.43x	1.43x	CN¥113.05 Million
2018	14.77%	26.54%	0.36x	1.53x	CN¥150.62 Million
2019	10.32%	24.99%	0.32x	1.29x	CN¥14.69 Million
2020	4.41%	30.57%	0.12x	1.17x	CN¥-580.80 Million
2021	5.58%	25.16%	0.15x	1.52x	CN¥-471.79 Million
2022	5.05%	22.66%	0.14x	1.63x	CN¥-541.63 Million
2023	3.28%	17.34%	0.11x	1.69x	CN¥-749.89 Million
2024	4.25%	16.53%	0.16x	1.65x	CN¥-661.74 Million

Industry Comparison

This section compares Cathay Biotech Inc's net assets metrics with peer companies in the Chemicals industry.

Industry Context

Industry: Chemicals
Average net assets among peers: $2,168,939,029
Average return on equity (ROE) among peers: 40.19%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Cathay Biotech Inc (688065)	CN¥21.22 Billion	11.94%	0.11x	$5.02 Billion
North Huajin Chemical Industries Co Ltd (000059)	$1.75 Billion	1.31%	0.67x	$1.22 Billion
Sichuan Chemical Co Ltd (000155)	$452.40 Million	20.36%	1.97x	$4.51 Billion
Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301)	$3.23 Billion	19.53%	0.36x	$12.43 Billion
Zangge Holding Co Ltd (000408)	$193.59 Million	324.78%	1.98x	$20.15 Billion
Sichuan Jinlu Group Co Ltd (000510)	$1.10 Billion	7.29%	1.92x	$1.56 Billion
Jilin Gpro Titanium Industry Co Ltd (000545)	$753.99 Million	12.59%	0.56x	$449.10 Million
Aoyuan Beauty Valley Technology Co Ltd (000615)	$671.47 Million	0.77%	1.87x	$881.48 Million
Ningxia Younglight Chemicals Co Ltd (000635)	$710.39 Million	13.66%	4.24x	$484.46 Million
Maoming Petro-Chemical Shihua Co Ltd (000637)	$723.47 Million	1.02%	0.01x	$363.63 Million
Inner Mongolia Yuan Xing Energy Co Ltd (000683)	$12.10 Billion	0.56%	0.92x	$4.71 Billion

About Cathay Biotech Inc

SHG:688065 China Chemicals

Market Cap

$5.02 Billion

CN¥34.33 Billion CNY

Market Cap Rank

#3614 Global

#578 in China

Share Price

CN¥47.60

Change (1 day)

-0.56%

52-Week Range

CN¥45.43 - CN¥62.24

All Time High

CN¥134.07